Realogy Names Longtime Franchise And Brokerage Leader Susan Yannaccone President And CEO Of Realogy Franchise Group

PR Newswire

MADISON, N.J., Nov. 17, 2020 /PRNewswire/ — Realogy Holdings Corp (NYSE: RLGY), the largest full-service residential real estate services company in the United States, today announced the appointment of Susan Yannaccone as president and chief executive officer of Realogy Franchise Group LLC, effective November 30, 2020. Yannaccone will replace John W. Peyton, who today was announced as the new chief executive officer of Dine Brands Global, Inc.

Yannaccone joined Realogy in 2015, and in her new role, she will oversee the franchise operations of Better Homes and Gardens® Real Estate, CENTURY 21®, and ERA®, as well as the franchise and owned operations of Sotheby’s International Realty® and Corcoran®. Yannaccone will report to Ryan Schneider, Realogy’s chief executive officer and president.

“Sue is an exceptional leader who brings deep expertise running both franchise and brokerage businesses at Realogy and within the industry over the past 20 years,” said Schneider. “I am incredibly excited to work with Sue and our brand leaders to further grow our powerful brands for our franchise owners and affiliated agents.”

During her tenure at Realogy, Yannaccone has held senior franchise and owned brokerage leadership positions. Before joining the company, she had more than 15 years’ franchise experience in both commercial and residential real estate and has consistently been recognized as a leader within the industry. Yannaccone recently launched the “What Moves Her” campaign, focused on helping women in real estate develop their professional goals and leadership across the industry.

“Real estate, particularly helping entrepreneurs and small business owners grow their businesses, has been a passion of mine all my career,” said Yannaccone. “I am proud to take on the management of Realogy Franchise Group, particularly as the first woman to hold this role, and I look forward to working closely with our franchise leaders to further position our brands and owners for continued growth.”

“I am proud of Realogy’s talent development, which prepares leaders, like Sue and John, for what’s next in their careers,” Schneider concluded. “I am very much looking forward to working with Sue in her new role, and I greatly appreciate John’s leadership during his time at Realogy. I wish him well in this new opportunity as he returns to hospitality.”

About Realogy Holdings Corp.
Realogy Holdings Corp. (NYSE: RLGY) is the leading and most integrated provider of U.S. residential real estate services, encompassing franchise, brokerage, relocation, and title and settlement businesses as well as a mortgage joint venture. Realogy’s diverse brand portfolio includes some of the most recognized names in real estate: Better Homes and Gardens® Real Estate, CENTURY 21®, Coldwell Banker®, Coldwell Banker Commercial®, Corcoran®, ERA®, and Sotheby’s International Realty®. Using innovative technology, data and marketing products, best-in-class learning and support services, and high-quality lead generation programs, Realogy fuels the productivity of independent sales agents, helping them build stronger businesses and best serve today’s consumers. Realogy’s affiliated brokerages operate around the world with approximately 189,000 independent sales agents in the United States and more than 129,000 independent sales agents in 114 other countries and territories. Recognized for nine consecutive years as one of the World’s Most Ethical Companies, Realogy has also been designated a Great Place to Work three years in a row and one of Forbes’ Best Employers for Diversity. Realogy is headquartered in Madison, New Jersey.

Forward Looking Statements

Certain statements in this press release constitute “forward-looking statements.” Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements, including statements regarding expectations with respect to future leadership changes. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Realogy Holdings Corp. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. 

Various factors that could cause actual future results and other future events to differ materially from those in forward-looking statements include but are not limited to those set forth under the headings “Forward-Looking Statements” and “Risk Factors” in Realogy’s filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, its Annual Report on Form 10-K for the year ended December 31, 2019, and its other filings made from time to time. Realogy undertakes no obligation to release publicly any revisions to any forward-looking statements, except as required by law.


Investor Contacts:


Media Contacts:

Alicia Swift

Trey Sarten

(973) 407-4669

(973) 407-2162


[email protected] 


[email protected]

Danielle Kloeblen

Kathleen LeFebvre

(973) 407-2148

(973) 407-2171


[email protected] 


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/realogy-names-longtime-franchise-and-brokerage-leader-susan-yannaccone-president-and-ceo-of-realogy-franchise-group-301174547.html

SOURCE Realogy Holdings Corp.

Results from Study Using Biocept’s Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®

PR Newswire

SAN DIEGO, Nov. 17, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that results from a prospective study using Target Selector™ testing to monitor disease progression in patients with metastatic breast cancer will be featured in a poster presentation at the virtual 2020 San Antonio Breast Cancer Symposium® (SABCS) on December 9, 2020. 

Vered Stearns, M.D., professor of oncology, breast cancer research chair in oncology, and director of the Women’s Malignancies Disease Group at Johns Hopkins University School of Medicine/Johns Hopkins Kimmel Cancer Center, will present “HER2 expression in matched metastatic tumor and circulating tumor cells (CTCs) in breast cancer: implications for profiling and monitoring of HER2 status to help guide anti-HER2 therapy.”  Following Dr. Stearns’ presentation, Biocept plans to announce the study results and to post the presentation here.

Despite improvements in early detection, one in eight women in the U.S. (12%) will develop invasive breast cancer over the course of her lifetime.  Approximately 20% of breast cancers test positive for the HER2 protein and, during treatment and with disease progression, the HER2 receptor may convert from positive to negative. 

“Once breast cancer metastasizes, it may be difficult to access multiple metastatic sites or to perform serial tissue biopsies to determine whether HER2 conversion has occurred,” said Dr. Steans.  “This prospective study was designed to evaluate the use of liquid biopsy compared with tissue biopsy for analysis of HER2 status over time.”

“The ability to monitor changes in tumor alterations can provide critical information for physicians in reassessing options over the course of treating patients with metastatic breast cancer,” said Michael Nall, President and CEO of Biocept.  “We believe that our Target Selector™ is among the most sensitive blood-based tests for identifying HER2 amplification.  It is highly gratifying to conduct this study with Dr. Stearns, a recognized leader in breast cancer research, and to have these results presented at the SABCS.”

About SABCS®
Since 1977 the San Antonio Breast Cancer Symposium® (SABCS®) has been the leading scientific conference for basic scientists, physician-scientists, clinical investigators and breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer.  Founded, owned, and operated by UT Health San Antonio, the symposium has grown to a five-day event attended by an international audience of academic investigators and private physicians from over 80 countries to attain information through abstract presentations, panel discussions, research findings, and state-of-the-art educational sessions.  UT Health San Antonio, the American Association for Cancer Research (AACR), and Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine support SABCS, which provides education and accessibility to the latest information regarding the prevention, diagnosis, and treatment of premalignant breast cancer and breast disease.  For more information about the symposium, please visit www.sabcs.org.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.  The Company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA).  With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.  Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic.  For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding Biocept’s plans to announce study results, the ability of our tests to provide clinically actionable information and the ability of Biocept’s platform to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings, including under the “Risk Factors” heading of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.


Investor Contact

:
 

LHA Investor Relations

Jody Cain

[email protected] 
310-691-7100

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/results-from-study-using-biocepts-target-selector-testing-to-monitor-breast-cancer-disease-progression-to-be-presented-at-2020-sabcs-301174553.html

SOURCE Biocept, Inc.

Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

  • S
    potlight
    p
    oster
    on
    updated PFS and OS data
    from the pivotal Phase 3
    clinical trial of
    o
    ral
    p
    aclitaxel
    in metastatic breast cancer

BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar (“oral paclitaxel”) data will be presented in four separate poster presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) to be held virtually December 8-11. Presentations will include, from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer (MBC), a spotlight poster on progression-free survival (PFS) and overall survival (OS), and posters on neuropathy (CIPN), and management of gastrointestinal (GI) side effects. An additional poster explores oral paclitaxel in the treatment of cutaneous angiosarcoma of the breast.

The symposium will also feature an immersive Athenex Oncology virtual exhibit experience with distinct hubs for CIPN, Medical Affairs, and the Facing MBC Together program.

Details of the oral paclitaxel presentations are as follows:


Spotlight Poster Presentation

Abstract Title:

Oral Paclitaxel and Encequidar (oPac+E) versus IV


P


aclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (Study: KX-ORAX-001)

Session:
Spotlight Poster Discussion 1

Program Number:
PD1-08

Date and Time:
Wednesday, December 9, 2020, at 4:00
PM
to 5:15
PM
Central Time (
CT
)

For more information, please visit:
https://www.sabcs.org/Program/Spotlight-Sessions/Spotlight-Poster-Discussion-1

Abstracts selected for spotlight poster presentation will only have titles posted to the SABCS website until the embargo lifts on December 9, 2020, when the complete abstract will post online.


Additional


Poster Presentations

Abstract Title:

A phase 2 study of


O


ral


P


aclitaxel and


E


ncequidar (oPac+E) in the treatment of cutaneous angiosarcoma: the breast angiosarcoma group

Program Number:
PS13-05

Session:
Poster Session 13

Date and Time:
Wednesday, December 9, 2020, at 8
:00
AM CT

For more information, please visit:
https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13



Abstract Title:


Lower rates of neuropathy with Oral Paclitaxel and Encequidar (oPac+E) compared to IV Paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001

Program Number:
PS13-06

Session:
Poster Session 13

Date and Time:
Wednesday, December 9, 2020, at 8:00 AM CT

For more information, please visit:
https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13



Abstract Title:


Oral Paclitaxel and Encequidar (oPac+E) in the treatment of metastatic breast cancer (mBC): Management of gastrointestinal adverse events (GI AE). Study KX-ORAX-001

Program Number:
PS13-11

Session:
Poster Session 13

Date and Time:
Wednesday, December 9, 2020, at 8
:00
AM CT

For more information, please visit:
https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-13



Athenex Exhibit Booth

Athenex Oncology will have an immersive virtual exhibit experience at SABCS. This unique booth will feature three separate hubs: 1) Chemotherapy-Induced Peripheral Neuropathy (CIPN) augmented reality simulation, designed to deepen a visitor’s understanding and virtually experience what it feels like to have CIPN; 2) Facing MBC Together, a public education and patient support program that addresses the issue of isolation for people living with metastatic breast cancer; and 3) Medical Affairs, where visitors can learn about how inhibition of P-gp facilitates absorption of orally administered chemotherapies. The booth will be accessible to meeting registrants throughout SABCS during exhibit hall hours, which are from 10am-7pm on Tuesday, December 8; 8am-7:45pm on Wednesday, December 9; and 10am-5pm on Thursday and Friday, December 10 and 11 (all Central Time). 

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit www.athenex.com.

About Oral Paclitaxel

Athenex’s oral paclitaxel and encequidar (“oral paclitaxel”) is the first oral formulation of paclitaxel in late-stage development for the treatment of metastatic breast cancer (MBC), and is also in earlier stages of development for other malignancies. Data from a pivotal phase 3, open-label, randomized, multicenter study involving more than 400 patients with MBC suggests that oral paclitaxel is superior to IV paclitaxel in terms of efficacy (as measured by confirmed tumor response) and tolerability. Encequidar, the cornerstone of Athenex’s Orascovery technology platform, is a highly specific and potent inhibitor of an active transport protein called P-glycoprotein (P-gp) in the gastrointestinal (GI) tract. By localizing P-gp inhibitory activity in the GI tract, encequidar improves the absorption of chemotherapeutic agents while limiting the potential for unnecessary P-gp inhibition at other sites in the body. The potency, selectivity, and non-systemic absorption of encequidar enables the administration of many traditional IV chemotherapies more easily, allowing for greater bioavailability and a potentially longer duration of therapy. On September 1, 2020, Athenex announced that the FDA accepted the Company’s New Drug Application (NDA) for Oral Paclitaxel for the treatment of MBC and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2021.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; uncertainties around our ability to meet funding conditions under our financing agreements and access to capital thereunder; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTS

Investors

Steve Rubis
Athenex, Inc.
Email: [email protected]

Daniel Lang, MD
Athenex, Inc.
Email: [email protected]

Media

Gloria Gasaatura
LifeSci Advisors, LLC
Email: [email protected]



Chipotle Royalty Gives Fans The Chance to Have their Go-To Orders Become Real Menu Items

Three winners can win $10,000 for their Chipotle orders

PR Newswire

NEWPORT BEACH, Calif., Nov. 17, 2020 /PRNewswire/ — Chipotle Mexican Grill (NYSE: CMG) today announced it is launching Chipotle Royalty with super-fan and digital star David Dobrik. The new competition will challenge fans to prove why their Chipotle order is the best among millions of possible combinations, and three winners will have their go-to bowl, burrito, salad or taco order featured as an official menu item on the Chipotle app and Chipotle.com for a limited time. Each winning fan will score $10,000 in cash for their featured menu item.

For more information on Chipotle Royalty, fans can visit: www.chipotle.com/royalty.


Make Your Order Famous

To enter, fans must post a creative TikTok video explaining why their Chipotle order is superior, using #ChipotleRoyalty and #contest. The contest period begins today and ends at 11:59pm PT on November 19. Dobrik and Chipotle Executive Chef Chad Brauze will be reviewing entries, judging on creativity and flavor combinations, and commenting on the winners’ posts on November 20. The winning menu items will be included in the featured section of the Chipotle app and Chipotle.com starting December 1 and available through the end of 2020.

Dobrik’s TikTok kicking off the competition can be found here: https://vm.tiktok.com/ZMJx915jo/.

“With more than four million possible menu item combinations, Chipotle fans are extremely passionate about their individual orders,” said Chris Brandt, Chief Marketing Officer. “Our fans are as unique as their orders and we look forward to hearing their stories and immortalizing a few of them as Chipotle Royalty.”


The Royal Family

Dobrik was the first celebrity to have his order, the Dobrik Burrito, featured as an official menu item on the Chipotle app and Chipotle.com on National Burrito Day in 2019. Over the past two years, Chipotle has teamed up with a variety of sports stars and wellness influencers for customized menu items. Chipotle Royalty marks the first time the brand is giving all fans the chance to have their go-to menu item featured on its digital ordering channels.

NO PURCHASE NECESSARY.  Open to legal residents of the U.S., 13 years or older (minors must have parental consent).  Enter between approx. 12:01 am PT on 11/17/20 – approx. 11:59 pm PT on 11/19/20. Prizes will be delivered in January 2021.  For Official Rules including how to enter, entry limitations and prize descriptions, visit www.chipotle.com/royalty. Sponsor: CMG Strategy Co., LLC, 610 Newport Center Drive, Suite 1400, Newport Beach, California, 92660.

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. Chipotle had over 2,700 restaurants as of September 30, 2020, in the United States, Canada, the United Kingdom, France and Germany and is the only restaurant company of its size that owns and operates all its restaurants. With more than 94,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. Steve Ells, founder and former executive chairman, first opened Chipotle with a single restaurant in Denver, Colorado in 1993. For more information or to place an order online, visit  WWW.CHIPOTLE.COM.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/chipotle-royalty-gives-fans-the-chance-to-have-their-go-to-orders-become-real-menu-items-301174537.html

SOURCE Chipotle Mexican Grill, Inc.

Health First Enhances Caring, Compassion and Connections with Families Using Vocera Ease

Health First Enhances Caring, Compassion and Connections with Families Using Vocera Ease

Patients’ loved ones give thumbs up to care teams and new mobile app

SAN JOSE, Calif.–(BUSINESS WIRE)–Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Health First deployed the Vocera Ease application in its four Central Florida hospitals to improve patient and family communication. The cloud-based application enables nurses and other healthcare professionals to send secure texts, photos and video updates to a patient’s designated loved ones during a hospital stay or medical procedure. Family members and friends can respond to updates with emojis, giving immediate feedback and support to caregivers.

Between April 15 and Oct. 2 of this year, Health First’s Holmes Regional Medical Center sent nearly 19,000 secure messages to patients’ loved ones across 49 states. In turn, these families and friends responded to care teams with more than 26,000 emojis, including 13,000 thumbs-ups, 8,000 hearts and 4,500 prayer hands.

“Even during the best of times, a hospital stay can cause anxiety for patients and their families. Not only are they dealing with a medical procedure, but they often can’t be together in the hospital. Seeing a reassuring picture of grandma or a newborn family member provides needed comfort,” said Mark Rosenbloom, M.D., FACS, CPE, Vice President of Clinical Transformation at Health First. “We are dedicated to providing the best possible healthcare experience and hope having access to the Vocera Ease application will help our patients’ and their loved ones feel cared for and have more peace of mind.”

Health First can track patient and family experience in real-time using the customizable in-app survey. Based on operating room survey results between April and October 2020 at Holmes Regional Medical Center, 97% of respondents indicated the hospital demonstrated compassion and caring by offering the Ease app to patients and families. Additionally, 97% said they would recommend the hospital to others based on their experience with the application.

In addition to Holmes Regional Medical Center, Health First’s Cape Canaveral Hospital, Health First’s Palm Bay Hospital and Health First’s Viera Hospital use the Ease application in operating rooms (OR) and newborn intensive care units (NICU). The mobile solution connects families and loved ones, no matter where they are, and helps support social distancing measures required by COVID-19 protocols.

Care teams can send secure updates from the OR, NICU, ICU, radiology, the emergency room, and other inpatient and outpatient areas The HIPAA-compliant messages, pictures and videos disappear 60 seconds after being viewed, and nothing is saved on the mobile device, providing an additional layer of security and privacy. The Ease application also provides secure two-way video conferencing between patients’ families and care teams.

“We are proud to support Health First, a long-time Vocera customer, as it continues improving communication and the healthcare experience for all,” said Brent Lang, Chairman and CEO of Vocera. “Restoring human connections, and helping improve the lives of patients, families and care teams is part of our core mission, which is so critical during a time when many of us can feel disconnected.”

About Health First

Founded in 1995, Health First is Brevard County’s not-for-profit, community healthcare system. The fully integrated delivery network (IDN) includes health insurance plans, hospitals, a multi-specialty medical group, and outpatient and wellness services. As a locally owned, not-for-profit organization, Health First is committed to investing in our community. In 2019, Health First provided more than $180 million in community support. To learn more about Health First and how we’re giving back to our community, please visit HFgivesback.org.

About Vocera

The mission of Vocera Communications, Inc. is to simplify and improve the lives of healthcare professionals, patients, and families while enabling hospitals to enhance quality of care and operational efficiency and humanize the healthcare experience. In 2000, when the company was founded, we began to forever change the way care teams communicate. Today, Vocera offers the leading platform for improving clinical communication and workflow. More than 2,100 facilities worldwide, including nearly 1,700 hospitals and healthcare facilities, have selected our solutions. Care team members use our solutions to communicate and collaborate with co-workers by securely texting or calling, and to be notified of important alerts and alarms. They can choose the right device for their role or task, including smartphones or our hands-free, wearable Vocera Smartbadge and Vocera Badge. They can create a richer, more human connection for patients and their loved ones before, during, and after care using Vocera Ease applications. Interoperability between the Vocera Platform and more than 150 clinical and operational systems helps reduce alarm fatigue; speed up staff response times; and improve patient care, safety, and experience. In addition to healthcare, Vocera solutions are found in luxury hotels, aged care facilities, retail stores, schools, power facilities, libraries, and more. Vocera solutions make mobile workers safer and more effective by enabling them to connect instantly with other people and access resources or information quickly. Vocera has made the list of Forbes 100 Most Trustworthy Companies in America. Learn more at www.vocera.com, and follow @VoceraComm and @VoceraEase on Twitter.

Vocera® and the Vocera logo are trademarks of Vocera Communications, Inc. registered in the United States and other jurisdictions. All other trademarks appearing in this release are the property of their respective owners.

Shanna Hearon

Vocera Communications, Inc.

669-999-3368

[email protected]

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Technology Mobile/Wireless Health Family Consumer Other Technology Telecommunications Parenting Software Children General Health Hospitals Other Consumer Seniors

MEDIA:

Logo
Logo

Author’s Memoir Teaches Readers Not to Judge a Book by its cover, or a Person by their Upbringing

“Ask Grandpaw” by Hank Visser is a memoir that explores the importance of persistence in the face of adversity

Lake Ann, MI, Nov. 17, 2020 (GLOBE NEWSWIRE) — Fast cars, farming, and faith all played a role in Hank Visser’s youth, but his upbringing wasn’t all that meets the eye. Visser’s memoir, “Ask Grandpaw” is the story of an underdog, or in this case, Hank and his eight siblings, all starting with nothing and their journeys to creating lives they can be proud of.  

 

Visser’s mother worked in a factory and was the primary breadwinner for their family, though Visser’s father had an arguably more chaotic job raising nine children- the firstborn in 1936 and the youngest born in 1954, all of whom are still alive today.

 

With little money, there was a constant stream of life lessons, most of which were learned out in the garden when the children worked for their meals.  As time marched on and the children grew older, Visser did ceramic tile work and was able to afford an antique car. A classic ride that demanded the spotlight when it outran state police on what would have otherwise been a quiet evening.  

 

“The importance of this book is for people to realize when you look at a stranger you can’t tell, without discussion, what kind of life brought that person to where they are now,” Visser said.

 

From humble beginnings to racing antique cars, Visser’s experience highlights the message that it does not matter where someone comes from, so long as they work hard and are a good person, they will end up exactly where they are meant to be. In this unprecedented time COVID-19 has prompted, losing everything is a harsh reality many people can relate to. Visser’s story will inspire those to push forward in the face of adversity and know there is always something better on the horizon.

 

“Ask Grandpaw”

By Hank Visser

ISBN: 9781489729774 (softcover); 9781489729767 (hardcover); 9781489729781 (electronic)

Available at the LifeRich Publishing Online Bookstore, Amazon, and Barnes & Noble

 

About the author

Hank Visser grew up in a large family with no luxury in the Grand Rapids area. Before becoming a tile setter by trade for over 60 years, Visser graduated from Caledonia Rural Agricultural Schools in 1958. Visser is an admirer of Dolly Parton, a loving father, grandfather, and great grandfather. He currently resides in Lake Ann, Michigan.

 


###


 

LifeRich Publishing, the strategic publishing partnership of Reader’s Digest and Author Solutions, LLC, was created to provide all writers a platform for sharing their stories, recipes, advice, and more. LifeRich authors will benefit from a wealth of editorial design, marketing and education resources, specially created by Reader’s Digest editors for the enrichment of these LifeSmart individuals. Books can be published in print, ebook or audio formats, with additional distribution to up to 25 million Reader’s Digest customers through its online properties. For more information or to publish a book, please visit liferichpublishing.com or call 1-888-238-8637.

Attachment



Kayla Rutledge
LAVIDGE
480-648-7540
[email protected]

EIS Customer Compass Report Finds Less than Half of Consumers Trust Insurers to Respond to Their Basic Needs

Online Transactions, Dynamic Pricing and Mobile Apps Cited as Top Three Consumer Priorities when Buying Insurance; Opportunities Abound for Digitally-Savvy Insurers

SAN FRANCISCO and LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — EIS, a core and digital platform provider for insurers, today announced the findings of its first-ever Customer Compass Report. The report found that, despite the insurance sector investing nearly $28 billion on customer experience, less than half of global respondents (49%) feel their insurance provider will be responsive to their basic needs. 

EIS, in partnership with GlobalWebIndex, surveyed 1,057 consumers who own insurance policies in the U.S., the UK, France and Germany, to generate insights into new expectations for customer experience found within the global insurance industry.

As insurers rapidly pivot their business and operational models in response to the global pandemic, those who will thrive in the New Normal will be the insurers who are prepared for digitally-enabled customer interactions. Globally, the top three most important factors for consumers when purchasing an insurance policy are: the ability to purchase products and services online (44%); secondly, the ability to offer dynamic pricing based on the individual consumer’s specific needs (42%); and, thirdly, having an easy-to-use mobile app (32%). 

When it comes to digital prowess, consumer opinions of insurers are astonishingly low – only 23% of consumers expect insurers to integrate their experience across mobile, web and in-person channels, while only 19% expect insurers will know them and their preferences following an interaction. This dynamic presents a terrific near-term opportunity for digitally-savvy insurers to exceed expectations and win business.

The data also shows insurers should be focused on how they can provide technology that empowers consumers to manage their financial lives. This sentiment was strongest in the UK, where 72% of respondents want to own and manage their financial lives digitally, compared to 65% and 63% for the U.S. and France respectively.

“Customer expectations outpacing insurer capabilities is the clarion call from our Customer Compass report,” said Anthony Grosso, Head of Global Marketing at EIS. “Getting user experience and personalization right across all digital channels is essential for insurers to meet consumer’s expectations for today’s digital lifestyle.”

“However, insurers who can rapidly re-architect their IT infrastructure to simplify the customer journey, create products that better meet lifestyle and life cycle needs can become the one-stop shop consumers crave,” Grosso added. “These insurers will build consumer confidence and grow their business within emerging consumer ecosystems.” 

Three key findings of the report bear this out:

  • Opportunity to own the customer lifecycle – There is a 36% gap between consumers who currently use one company for all their insurance needs, and those who would be happy to do so. This is a huge market opportunity being driven by access to new technology and modern pricing models. While 44% of consumers in France currently purchase all their insurance from a single provider, the gap is most pronounced in the UK where only 12% of consumers do the same, yet 60% are comfortable buying from a single provider.

  • Subscription and usage-based insurance provide control consumers want – The subscription business model has permeated how consumers access more and more products and services, and they want insurance to follow suit. 66% of those surveyed said they don’t like being tied into annual contracts, preferring to pay monthly, with the option to cancel at any time. The appeal is clear: for consumers, it is a simple, hassle-free offer; for insurers, it is recurring, predictable revenue which can enhance customer loyalty. This desire for control also extends to consumers being only charged based on how often they use services. UK consumers want this level of control the most at 67%, followed by the U.S. at 65% and France at 59%.

  • The power of bundling – The advent of open platforms and connected devices is also enabling innovative packaging of insurance and non-insurance products to drive revenue. For example, 55% of consumers were interested in a housing bundle including home insurance, financing, essential home repairs and all home utilities. UK and U.S. consumers showed more interest, at 51%, than French consumers, at 37%.

Download the Customer Compass Report

About
EIS

EIS is an insurance software company that enables leading insurers to innovate and operate like a tech company: fast, simple, agile. Founded in 2008, EIS provides a platform for high-velocity insurance. This open, flexible platform of core and digital solutions liberates insurers to accelerate innovation, launch products faster, deliver new revenue channels, and create insurance experiences the world will love. And with thousands of APIs, the platform gives insurers the freedom to connect to a vast ecosystem of insurtech and emerging technologies. Headquartered in San Francisco, EIS powers premium growth for P&C and Life insurance companies worldwide. For more information on how EIS helps insurers become unbeatably fast at everything they do, visit EISGroup.com.

UK Media contact:
Hotwire for EIS
Ed Stevenson/Banke Koledoye
[email protected]
0207 608 4622

U.S. Media Contact:
Liam Collopy
Harden Communications Partners
[email protected]
415.517.9760

 



Equinix Invests $200 Million in Washington, D.C. Area Data Center Expansions

Businesses Increasingly Utilizing Equinix Ashburn Campus as Key Component of their Digital Infrastructure

PR Newswire

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company, today announced further expansion in the Washington, D.C. area with the opening of its 16th International Business Exchange™ (IBX®) data center, DC21. With the addition of DC21, as well as the opening of the DC15 data center earlier this year, Equinix has invested more than $200 million in the Washington, D.C. area in 2020, as the area remains one of the most highly interconnected regions powering the global digital economy. The new facilities strengthen Equinix’s position as a leading digital infrastructure and service provider in the Washington, D.C. metro area offering businesses, as well as multinationals, increased opportunities to leverage a trusted platform to bring together and interconnect the foundational infrastructure to power their success.

Equinix’s newest Washington, D.C. area data centers are part of Equinix’s data center campus in Ashburn, VA, home to the largest internet peering point in North America and one of the largest in the world—a strategic communications hub for the eastern U.S. and a major gateway to Europe. The expansion of its Ashburn Campus will provide Equinix additional capacity to respond to accelerating customer demand within the rapidly growing enterprise, government, cloud and financial services industries.

The Washington, D.C. area is one of four markets that includes Equinix Metal™, a new, fully automated and interconnected bare metal service launched in October. With this new service, companies have the option to deploy the physical infrastructure of their choice at software speed across Equinix’s trusted platform. Together with other digital infrastructure building blocks in the Equinix portfolio, customers now have a broad range of physical and virtual deployment alternatives to place infrastructure wherever they need it and connect to everything they need to succeed.

The expansion of the Equinix Ashburn Campus also includes a Co-Innovation Facility (CIF) where leading technology vendors in the digital infrastructure space can test, demonstrate and evolve their products in collaboration with Equinix. The CIF is a new capability, hosted by Equinix, that enables innovative suppliers to work with Equinix on trialing and developing methodologies that will be used to help define the future of digital infrastructure and services.

Highlights / Key Facts

  • DC21 is a two-story, state-of-the-art data center designed to deliver both small- and large-capacity deployments. The innovative, modular construction incorporates Equinix’s Flexible Data Center (FDC) principles, which leverage common design elements for space, power and cooling to reduce capital costs while ensuring long-term maintenance predictability. The $95 million first phase of DC21 will provide more than 41,000 square feet of colocation space, offering an initial capacity of 925 cabinets. Upon completion of the planned future phases, DC21 is expected to provide total capacity of 3,100 cabinet equivalents and colocation space of more than 124,000 square feet.
  • The $111 million first phase of DC15 opened in Q2 2020 with an initial capacity of 1,600 cabinet equivalents and colocation space of approximately 23,000 square feet.
  • The Washington, D.C. metro represents the largest colocation market in the U.S. and, with the opening of DC21, includes 16 Equinix IBX data centers that house more than 200 network service providers—more than any other data center provider in the Washington D.C. metro area. The Equinix Ashburn campus is the single most-dense interconnection hub in the U.S., providing proximity to financial enterprises, content and digital media services, global networks and cloud service provider. 
  • The Equinix Ashburn Campus provides a wide range of interconnection solutions, including Equinix FabricTM — formerly Equinix Cloud Exchange Fabric. Equinix Fabric is an on-demand, SDN-enabled interconnection service that allows any business to connect between its own distributed infrastructure and any other company’s distributed infrastructure, including the world’s largest network service and cloud providers on Platform Equinix®. Through Equinix Fabric, customers in Ashburn can set up direct connectivity with international and local cloud service providers across the U.S., including Alibaba, AWS, Google Cloud, Microsoft Azure, Oracle Cloud, SAP Cloud and SoftLayer, as well as major network service providers.
  • Equinix’s long-term goal of using 100% clean and renewable energy for its global platform has resulted in significant increases in renewable energy coverage globally, including 100% renewable throughout the U.S. Equinix continues to make advancements in the way it designs, builds and operates its global platform, with high energy efficiency standards. DC21 and other Equinix Ashburn campus customers canl benefit from reductions of their CO2 footprint through Equinix’s renewable energy procurement strategy and the use of energy-efficient systems throughout these facilities.
  • Currently, the global footprint of Platform Equinix spans more than 225 IBX data centers across 63 markets and 26 countries, providing digital infrastructure and services for more than 9,500 of the world’s leading businesses. In the U.S, Equinix has more than 80 IBX data centers across key metros, including Silicon Valley, Dallas, Chicago, New York, Miami and Washington, D.C.

Quotes


  • Kelly Morgan, Research Director at 451 Research, part of S&P Global Market Intelligence

    “Ashburn, in Loudon County just outside of Washington, D.C., is a central connectivity hub and critically important to the U.S. cloud and infrastructure story. Enterprises that previously did not see a need to improve networks may now, as a result of the pandemic, be open to new approaches and ready to try network hubs. This is placing an increased focus on data centers that can offer direct connections to the cloud with private on-ramps.”

  • Jon Lin, President, Americas, Equinix:

    “D.C. continues to prosper as a key digital hub for businesses around the world despite the challenges faced with the COVID-19 pandemic. Our continued expansion in this important metro creates more opportunities for businesses to leverage Platform Equinix as the central component to their digital foundation while enabling them to grow and scale at software speed.” 

Additional Resources

About Equinix

Equinix (Nasdaq: EQIX) is the world’s digital infrastructure company, enabling digital leaders to harness a trusted platform to bring together and interconnect the foundational infrastructure that powers their success. Equinix enables today’s businesses to access all the right places, partners and possibilities they need to accelerate advantage. With Equinix, they can scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements. Factors that might cause such differences include, but are not limited to, the challenges of acquiring, operating and constructing IBX® data centers and developing, deploying and delivering Equinix products and solutions; unanticipated costs or difficulties relating to the integration of companies we have acquired or will acquire into Equinix; a failure to receive significant revenues from customers in recently built out or acquired data centers; a failure to complete any financing arrangements contemplated from time to time; competition from existing and new competitors; the ability to generate sufficient cash flow or otherwise obtain funds to repay new or outstanding indebtedness; the loss or decline in business from our key customers; risks related to our taxation as a REIT; and other risks described from time to time in Equinix filings with the Securities and Exchange Commission. In particular, see recent Equinix quarterly and annual reports filed with the Securities and Exchange Commission, copies of which are available upon request from Equinix. Equinix does not assume any obligation to update the forward-looking information contained in this press release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/equinix-invests-200-million-in-washington-dc-area-data-center-expansions-301174519.html

SOURCE Equinix, Inc.

Quantum Expands ActiveScale Object Storage Portfolio, Bolstering Security and Performance

ActiveScale Brings Data Immutability to a Lower Entry Point

PR Newswire

SAN JOSE, Calif., Nov. 17, 2020 /PRNewswire/ — Quantum Corp. (NASDAQ: QMCO) today announced enhancements to its ActiveScale™ platform with a focus on data security, increased capacity efficiency and performance. The company also added a more compact, entry level configuration to its portfolio. The new capabilities advance Quantum’s strategy to be the leading provider of management and storage services for unstructured data.

“With data quickly becoming the most valuable asset for many enterprises and critical for business survival, object storage is emerging as the preferred archive format to handle massive unstructured data growth,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group, IDC. “Enterprises seeking to monetize their growing data stores will clearly benefit from the efficient, highly available, secure and scalable unstructured storage platforms vendors like Quantum are bringing to the market.”

Helping Data-Driven Enterprises Manage, Protect, and Preserve Their Most Valuable Asset
Increasingly, double digit data growth rates are exacerbating the cost and complexity of managing and storing data. The ability of organizations to extract value from data is essential to staying competitive, which drives the demand for data availability and access. Magnifying this challenge is the scale at which data and storage must be managed. ActiveScale object storage platform meets the necessity of managing, protecting, and preserving data at scale.

Quantum ActiveScale software delivers flexible scalability, from a few hundred terabytes to tens of petabytes, with its Dynamic Data Placement model assuring the highest levels of data durability. ActiveScale features and architecture simplify the deployment and management of the environment today and into the future.

“Digital media infrastructures have never been more dependent on technologies that help to secure assets and keep them available for increasingly demanding workflows,” said Barry Fairhurst, CEO, F2 Technologies Inc. “Quantum’s ActiveScale object storage offerings come at a time when many companies are reevaluating how they can better manage and protect their data assets in a scalable way to stay competitive in a challenging environment.”

ActiveScale Object Lock for Data Immutability
The new ActiveScale 5.7 Object Lock feature protects data from malicious acts such as data deletion, relocation, and ransomware. Once immutability is set on an object or a bucket, it can’t be modified until the policy expires. Whether for compliance or protection against data loss, object lock ensures the data will be the same days, months, or years later.

Small Object Aggregation for Enhanced Efficiency and Performance
The ActiveScale platform has a new Small Object Aggregation capability that enhances its ability to provide efficient storage capacity by aggregating small files into a large object prior to erasure encoding it. The aggregation results in higher utilization and increased overall performance for small object transactions. The key differentiator of small object aggregation is the ability of ActiveScale to provide direct access to small objects without reconstituting the whole object. 

New Entry-Level Capacity
Quantum enhanced the ActiveScale architecture, now offering a smaller, three-node configuration starting at 432TB raw. With this entry-level option customers can benefit from the management, protection, and preservation capabilities of ActiveScale as they grow.

“This new entry point will enable more customers to deploy best-in-class object storage at a lower capacity and grow cost-effectively,” said Bruno Hald, General Manager, Secondary Storage, Quantum. “With this expanded ActiveScale object storage portfolio, customers gain features to more capably manage their data, defend it against ransomware threats with Object Lock, and preserve it indefinitely.”

Additional Resources

About Quantum
Quantum technology and services help customers capture, create and share digital content – and preserve and protect it for decades.  With solutions built for every stage of the data lifecycle, Quantum’s platforms provide the fastest performance for high-resolution video, images, and industrial IoT.  That’s why the world’s leading entertainment companies, sports franchises, researchers, government agencies, enterprises, and cloud providers are making the world happier, safer, and smarter on Quantum.  Quantum is listed on Nasdaq (QMCO) and was added to the Russell 2000® Index in 2020. For more information visit www.quantum.com/.

Quantum and the Quantum logo are registered trademarks of Quantum Corporation, and ActiveScale is a trademark of Quantum Corporation. All other trademarks are the property of their respective owners.

Forward-Looking Statements
This press release contains “forward-looking” statements. Quantum advises caution in reliance on forward-looking statements. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of Quantum Corporation and its consolidated subsidiaries (“Quantum”) may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements regarding the ActiveScale object storage platform meeting the necessity of managing, protecting, and preserving data at scale, and its ability to manage and protect the user’s data assets in a scalable way to allow the user to stay competitive in a challenging environment. Risks, uncertainties and assumptions include the risk that StorNext 6.4 is not accepted by hybrid cloud and multi-cloud storage users, and other risks that are described herein, including but not limited to the items discussed in “Risk Factors” in Quantum’s filings with the Securities and Exchange Commission, including its Form 10-K filed with the Securities and Exchange Committee on August 6, 2019. Quantum expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Public Relations Contact:

Bob Wientzen

Quantum Corp.
+1 (720) 201-8125
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/quantum-expands-activescale-object-storage-portfolio-bolstering-security-and-performance-301174554.html

SOURCE Quantum Corp.

Veradigm and HealthVerity Expand Existing Partnership with Novel Linked Real-World Data Packages

Veradigm and HealthVerity Expand Existing Partnership with Novel Linked Real-World Data Packages

Two solutions will initiate this extended collaboration focused on the linking of real-world data to both clinical trial data and specific therapeutic area data.

CHICAGO–(BUSINESS WIRE)–
Veradigm®, an Allscripts (NASDAQ: MDRX) business unit leading the industry with real-world data and analytic solutions, and HealthVerity, the leader in privacy-protected data exchange, today announced that they have entered into a strategic partnership that extends the companies’ current relationship. The initial focus is on the development of innovative HIPAA-compliant data products created by linking real-world data from a variety of leading sources. In addition to generalized real-world data linking capabilities, the companies will focus on addressing specific industry needs by enabling clients to design linked data solutions that are fit-for-purpose. Initially the companies will focus on two areas: linking real-world data within specific therapeutic areas (TAs) and a clinical research solution linking real-world data to clinical trial data.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005374/en/

These data packages are created by seamlessly linking data from Veradigm’s expansive electronic health records (EHR) registry and medical and pharmacy claims data, with lab, and other real-world data sources, including pharmacy and hospital chargemaster, depending on client-specific needs. Veradigm will leverage HealthVerity Marketplace, the nation’s largest ecosystem of healthcare and consumer data, to collaborate with owners of other real-world data sources, as necessary, providing turnkey linked data packages that are fit-for-purpose. The initial data package for COVID-19 is currently available, linking EHR, medical and pharmacy claims and lab data, offering unsurpassed data recency. Data for flu and/or other respiratory diseases can be included as requested. Future packages will focus on cardiometabolic disorders, autoimmune disorders and other TAs of interest.

In addition, the companies are offering a solution focused on the linkage of clinical trial data to real-world data. With HealthVerity Census, the near real-time identity resolution and matching technology, pharmaceutical trial data is tokenized with a unique and consistent identifier and subsequently linked to Veradigm’s EHR, claims and other broad-based data sources in a HIPAA-compliant manner. This linked solution creates a rich, robust and readily accessible dataset that can be delivered daily to better characterize the trial population, identify safety signals, and potentially provide evidence supporting secondary endpoints. Veradigm and HealthVerity will work closely with study sponsors to customize this solution to meet the objectives of each research project.

This collaboration into fit-for-purpose data packages builds upon a long-standing relationship between Veradigm and HealthVerity. By leveraging HealthVerity’s state-of-the-art platform, Veradigm has been able to unify all its data assets into common data models, ensuring interoperability across the HealthVerity data ecosystem. And, Veradigm provides HealthVerity with a large and rich source of clinical and claims data to include within its growing data ecosystem. The partnership provides an ability to develop unique solutions that are tailored to the needs of the market.

“We recognize that linked data from different sources creates a more complete view of the patient journey, but the linking process is resource-intensive and protecting privacy is of utmost importance,” said Tom Langan, CEO of Veradigm. “By working with HealthVerity and other leading real-world data suppliers, we can provide privacy-protected, turnkey, linked data solutions that solve intractable problems.”

“Given the interest our clients have in better understanding specific patient populations that require a longitudinal view of the patient journey, combined with deeper clinical granularity, our growing partnership with Veradigm helps continuously meet those needs,” said Andrew Kress, CEO and cofounder of HealthVerity. “Supporting Veradigm in both its internal and external data privacy and data management strategy is a great starting point to enable this ability for additional clients that require the same level of HIPAA-compliance and interoperability.”

About Veradigm®

Veradigm is an integrated data systems and services company that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery— including biopharma, health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. This is how we are transforming health, insightfully. To learn more, visit www.veradigm.com. Veradigm® is a business unit of Allscripts

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

About HealthVerity

Powering the largest healthcare and consumer data ecosystem, combined with best-in-class management and privacy solutions, HealthVerity is helping answer healthcare’s most critical questions. Our technology platform serves as the foundation for the rapid creation, exchange and management of healthcare and consumer data in a fully interoperable privacy-protecting manner. Advantaged by highly sophisticated identity resolution and matching capabilities, HealthVerity is on a mission to increase transparency, forge interoperability and activate deeper insights. To learn more about HealthVerity’s technology platform, visit www.healthverity.com.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Investors:

Stephen Shulstein

312-386-6735

[email protected]

Media:

Concetta Rasiarmos

312-447-2466

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Software General Health Health Data Management Technology Mobile/Wireless Other Technology Other Health

MEDIA:

Logo
Logo
Logo
Logo